Literature DB >> 20012093

MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects.

Chen Mao1, Li-Xin Qiu, Ping Zhan, Kai Xue, Hong Ding, Fang-Bing Du, Jin Li, Qing Chen.   

Abstract

PURPOSE: Published data on the association between manganese superoxide dismutase (MnSOD) Val(16)Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.
METHODS: PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.
RESULTS: A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00-1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00-1.49; for dominant model: OR = 1.14, 95% CI = 1.03-1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00-1.25; for dominant model: OR = 1.14, 95% CI = 1.02-1.26). However, no significant associations were found in Africans.
CONCLUSIONS: This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012093     DOI: 10.1007/s00432-009-0742-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.

Authors:  Sholom Wacholder; Stephen Chanock; Montserrat Garcia-Closas; Laure El Ghormli; Nathaniel Rothman
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.

Authors:  Haojie Li; Philip W Kantoff; Edward Giovannucci; Michael F Leitzmann; J Michael Gaziano; Meir J Stampfer; Jing Ma
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

4.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

Authors:  P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

5.  Expression of antioxidant enzymes in human prostatic adenocarcinoma.

Authors:  A M Baker; L W Oberley; M B Cohen
Journal:  Prostate       Date:  1997-09-01       Impact factor: 4.104

6.  Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland).

Authors:  Karen Woodson; Joseph A Tangrea; Teresa A Lehman; Ramakrishna Modali; Kristin M Taylor; Kirk Snyder; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Causes Control       Date:  2003-08       Impact factor: 2.506

7.  Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.

Authors:  H Arzu Ergen; Fehmi Narter; Ozlem Timirci; Turgay Isbir
Journal:  Anticancer Res       Date:  2007 Mar-Apr       Impact factor: 2.480

8.  MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status.

Authors:  Taro Iguchi; Shozo Sugita; Ching Y Wang; Nancy B Newman; Tatsuya Nakatani; Gabriel P Haas
Journal:  In Vivo       Date:  2009 Jan-Feb       Impact factor: 2.155

9.  MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells.

Authors:  Hong Duan; Hannah J Zhang; Ji-Qin Yang; Larry W Oberley; Bernard W Futscher; Frederick E Domann
Journal:  Antioxid Redox Signal       Date:  2003-10       Impact factor: 8.401

Review 10.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

View more
  16 in total

Review 1.  Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Authors:  Sang Wook Kang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Association between environmental tobacco smoke exposure and lung cancer susceptibility: modification by antioxidant enzyme genetic polymorphisms.

Authors:  Mona Fathy; Mai Hamed; Omnia Youssif; Nahla Fawzy; Wafa Ashour
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

3.  The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis.

Authors:  Maiquidieli Dal Berto; Claudia Giuliano Bica; Gustavo Pereira de Sá; Fernanda Barbisan; Verônica Farina Azzolin; Felipe Rogalski; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz
Journal:  Med Oncol       Date:  2015-10-14       Impact factor: 3.064

4.  Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.

Authors:  Erin L Van Blarigan; Jing Ma; Stacey A Kenfield; Meir J Stampfer; Howard D Sesso; Edward L Giovannucci; John S Witte; John W Erdman; June M Chan; Kathryn L Penney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-07       Impact factor: 4.254

5.  There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival.

Authors:  Chengdi Wang; Yang Liu; Jian Zhou; Lei Ye; Nan Chen; Min Zhu; Yulin Ji
Journal:  Mol Clin Oncol       Date:  2017-08-14

6.  A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer.

Authors:  Nihat Uluocak; Doğan Atılgan; Bekir Süha Parlaktaş; Fikret Erdemir; Ömer Ateş
Journal:  Turk J Urol       Date:  2017-07-31

7.  Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

Authors:  Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-06       Impact factor: 4.254

8.  Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Authors:  Channing J Paller; Xian C Zhou; Elisabeth I Heath; Mary-Ellen Taplin; Tina Mayer; Mark N Stein; Glenn J Bubley; Roberto Pili; Tamaro Hudson; Radhika Kakarla; Muneer M Abbas; Nicole M Anders; Donna Dowling; Serina King; Ashley B Bruns; William D Wagner; Charles G Drake; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade; Michelle A Rudek; Gary L Rosner; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2017-11-07       Impact factor: 12.531

9.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

10.  Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Authors:  Nur Ozten-Kandaş; Maarten C Bosland
Journal:  J Carcinog       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.